Browse by author
Lookup NU author(s): Professor Hilary Calvert
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Phase I studies of [N-(2-hydroxypropyl)methacrylamide] (HPMA) copolymer-doxorubicin previously showed signs of activity coupled with 5-fold decreased anthracycline toxicity in chemotherapy-refractory patients. Here we report phase II studies using a similar material (FCE28068) in patients with breast (n=17), non-small cell lung (NSCLC, n=29) and colorectal (n=16) cancer. Up to 8 courses of PK1 (280 mg/m2 doxorubicin-equivalent) were given i.v., together with 123I-labelled imaging analogue. Toxicities were tolerable, with grade 3 neutropenia more prominent in patients with breast cancer (4/17, 23.5% compared with 5/62, 8.1% overall). Of 14 evaluable patients with breast cancer 3 had partial responses (PR), all anthracycline-naïve patients. In 26 evaluable patients with NSCLC, 3 chemotherapy-naïve patients had PR. In contrast, none of the 16 evaluable patients with colorectal cancer responded. Imaging of 16 patients (5 with breast cancer, 6 NSCLC, 5 colorectal cancer) showed obvious tumour accumulation in 2 metastatic breast cancers, although unfortunately no images were obtained from patients who responded. These results show 6/62 PR with limited side effects, supporting the concept that polymer-bound therapeutics can have modified and improved anticancer activities and suggesting the approach should be explored further for breast cancer and NSCLC.
Author(s): Seymour L, Ferry D, Kerr D, Rea D, Whitlock M, Poyner R, Boivin C, Hesselewood S, Twelves C, Blackie R, Schatzlein A, Jodrell D, Bissett D, Calvert H, Lind M, Robbins A, Burtles S, Duncan R, Cassidy J
Publication type: Article
Publication status: Published
Journal: International Journal of Oncology
Year: 2009
Volume: 34
Issue: 6
Pages: 1629-1636
ISSN (print): 1019-6439
ISSN (electronic): 1791-2423
Publisher: Spandidos Publications
URL: http://dx.doi.org/10.3892/ijo_00000293
DOI: 10.3892/ijo_00000293
PubMed id: 19424581
Altmetrics provided by Altmetric
